13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001633313
Total reported value
$11.1B
$11.1B
46 檔
26.9%
According to the latest 13F quarterly dataset, Avoro Capital Advisors LLC managed an equity portfolio of $11.1B at the end of Q1 2024, spanning 46 distinct U.S. exchange-listed positions.
During Q1 2024, Avoro Capital Advisors LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, APLSUSD, ASND) accounted for 26.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 7.66% | -1.92% | — | |
| 2 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 7.62% | -4.84% | EXIT | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 6.99% | -11.39% | EXIT | |
| 4 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 6.56% | — | — | |
| 5 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 6.06% | -0.52% | +2.94% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.69% | +1.15% | +0.32% | |
| 7 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 5.30% | +2.30% | -0.39% | |
| 8 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 4.76% | — | -3.25% | |
| 9 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 4.45% | — | +1.51% | |
| 10 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.76% | — | — | |
| 11 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 3.73% | — | — | |
| 12 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 3.43% | — | — | |
| 13 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.85% | +1.71% | +657.13% | |
| 14 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.85% | -0.18% | — | |
| 15 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 2.67% | — | — | |
| 16 | VERA | Vera Therapeutics Inc | Stock-Other | 2.65% | -0.12% | — | |
| 17 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 2.02% | — | +74.63% | |
| 18 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.00% | — | +9.73% | |
| 19 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.82% | +1.58% | +3.02% | |
| 20 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.73% | — | +132.07% | |
| 21 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.51% | — | — | |
| 22 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.17% | — | — | |
| 23 | MGNX | Macrogenics Inc | Stock-Other | 1.06% | — | — | |
| 24 | KURA | Kura Oncology Inc | Stock-Other | 0.96% | — | +29.19% | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.92% | — | — | |
| 26 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.81% | — | — | |
| 27 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.81% | -0.76% | EXIT | |
| 28 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.77% | — | — | |
| 29 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.76% | +0.08% | — | |
| 30 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.62% | +0.51% | +328.19% | |
| 31 | TRML | Tourmaline Bio Inc | Stock-Other | 0.59% | — | +155.90% | |
| 32 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.57% | — | — | |
| 33 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.52% | — | -73.00% | |
| 34 | MNKD | Mannkind CORP | Stock-Other | 0.48% | -0.05% | EXIT | |
| 35 | ✓ | Merus N V | Stock-Other | 0.47% | — | — | |
| 36 | PCVX | Vaxcyte Inc | Stock-Other | 0.46% | — | — | |
| 37 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.45% | — | +137.14% | |
| 38 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.44% | — | +31.45% | |
| 39 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.40% | — | — | |
| 40 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 41 | CGON | Cg Oncology Inc | Stock-Other | 0.36% | — | — | |
| 42 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.33% | — | — | |
| 43 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.28% | — | — | |
| 44 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 45 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.08% | +0.02% | — | |
| 46 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, Avoro Capital Advisors LLC reported a total U.S. public equity portfolio value of $11.1B across 46 disclosed positions in Q1 2024.
During Q1 2024, Avoro Capital Advisors LLC's top holdings by market value included UTHR (7.7%)、APLSUSD (7.6%)、ASND (7.0%). The largest single position, UTHR, represented 7.7% of total portfolio value.
In Q1 2024, Avoro Capital Advisors LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.